the main ingredient of this product is bivalirudin.
chemical name: d-phenylalanyl-l-prolyl-l-arginyl-l-prolyl-glycyl-glycyl-glycyl-glycyl-l-asparagyl-glycyl-l-aspartyl-l-phenylalanyl-l-glutamyl-l-glutamyl-l-isoleucyl-l-prolyl-l-glutamyl-l-glutamyl-l-tyrosyl-l-leucine
molecular formula: c98h138n24o33
molecular weight: 2180.28
excipient: mannitol, sodium hydroxid
|【dosage and administration】
this product is used for intravenous injection and intravenous infusion.
the recommended dose of bivalirudin is an intravenous bolus dose of 0.75 mg/kg before pci, followed immediately by an infusion of 1.75 mg/kg/h for the duration of the pci procedure (not more than 4 hours). five minutes after the bolus dose has been administered, an activated clotting time (act) should be performed and an additional bolus of 0.3 mg/kg should be given if needed. after 4 hours, an additional iv infusion of bivalirudin may be initiated at a rate 0.2 mg/kg/h (low-rate infusion), for up to 20 hours, if needed. glycoprotein iib/iiia inhibitor (gpi) should be considered in the event that any of the conditions listed in the replace-2 clinical trial (see clinical trials) is present. for patients with hit/hitts undergoing pci, the recommended dose of bivalirudin is an iv bolus of 0.75 mg/kg. this should be followed by a continuous intravenous infusion at a rate of 1.75 mg/kg/h for the duration of pci procedure. bivalirudin is recommended for use with aspirin (300-325 mg per day).